Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): A randomised, open-label, phase 3 trial

Manfred Westphal*, Seppo Ylä-Herttuala, John Martin, Peter Warnke, Philippe Menei, David Eckland, Judith Kinley, Richard Kay, Zvi Ram

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): A randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences